ITGAX and neoplasm: These observations demonstrate that CD4+ effector T cells cluster with CD11c-Venus+ immune cells at the tumour invasive margin where they maintain prolonged antigen-specific and MHC-II-restricted interactions that enable them to eradicate MHC-deficient tumours.